News Tris cues up filing for non-opioid pain drug on phase 3 win Tris Pharma has set its sights on an FDA filing for non-opioid pain drug cebranopadol this year after hitting the mark in an abdominoplasty trial.
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.